• 中文版
  • Home
  • About Us
    • Contract Research Organization
    • Contract Development and Manufacturing Organization
    • Accolades
    • Publications
  • Services Overview
  • Discovery Chemistry
    • Synthetic Chemistry
    • Medicinal Chemistry
    • Library Chemistry
    • Peptide Chemistry
    • Fragment Based Screening
    • Computer Aided Drug Design
    • Analytical Services
    • Protein Structure
  • Biology & Pharmacology
    • Oncology
    • Pathology Core Facility
    • Immunology
    • Tumor Immunology
    • Neuroscience
    • Cell Biology
    • In Vitro Biology
      • Kinases
      • Epigenetics
      • GPCR, NR, Ion-channel, Transporter
      • Ubiquitin & PROTAC
      • KRAS
      • COVID-19
      • Radiometric
      • Customized assay development
      • High throughput screening
      • MOA Study
    • Metabolic & Cardiovascular Diseases
  • DMPK / Exploratory Toxicology
    • DMPK / Exploratory Toxicology
    • Biomarkers, Preclinical & Clinical Sample Bioanalysis
    • Large molecule PK/BA services
  • Biologics Discovery
    • Antibody Discovery
    • Protein Science
    • Biologics Analytical Services
    • B Cell Cloning
  • Biologics CMC
    • Stable Cell Line Development
    • Process Development
    • Formulation Development
    • Aseptic Filling and Freeze-drying
    • Drug Developability / Manufacturability study
    • Final Container Extractables & Leachables Study
    • Analytical Development and Testing
    • GMP Production
  • Small Molecule CMC
    • Process R&D Services
    • Process Safety
    • Analytical Development
    • Pre-Formulation Development
    • Formulation Development
    • ICH Stability Studies
    • CMC CTD Support
    • Manufacturing
  • Blog
  • Careers
  • News & Events
    • Webinars
  • Contact Us
  • Download Center

Call us today! +86 21 5132 0088

contact@chempartner.com
中文版
Shanghai ChemPartner Shanghai ChemPartner Shanghai ChemPartnerShanghai ChemPartner
  • Home
  • About Us
    • About ChemPartner
    • CRO
    • CDMO
    • Accolades
    • Publications
  • Services
    • Discovery Chemistry
      • Synthetic Chemistry
      • Medicinal Chemistry
      • Library Chemistry
      • Peptide Chemistry
      • Fragment Based Screening
      • Computer Aided Drug Design
      • Analytical Services
      • Protein Structure
    • Biology & Pharmacology
      • Oncology
      • Pathology Core Facility
      • Immunology
      • Tumor Immunology
      • Cell Biology
      • In Vitro Biology
      • Neuroscience
      • Metabolic & Cardiovascular Diseases
      • Epigenetics
    • DMPK / Exploratory Toxicology
      • DMPK / Exploratory Toxicology
      • Biomarkers, Preclinical & Clinical Sample Bioanalysis
      • Large molecule PK/BA services
    • Biologics Discovery
      • Antibody Discovery
      • Protein Science
      • Biologics Analytical Services
      • B Cell Cloning
    • Biologics CMC
      • Stable Cell Line Development
      • Process Development
      • Formulation Development
      • Aseptic Filling and Freeze-drying
      • Drug Developability / Manufacturability study
      • Final Container Extractables & Leachables Study
      • Analytical Development and Testing
      • GMP Production
    • Small Molecule CMC
      • Process R&D Services
      • Process Safety
      • Analytical Development
      • Pre-Formulation Development
      • Formulation Development
      • ICH Stability Studies
      • CMC CTD Support
      • Manufacturing
  • Blog
  • Careers
  • News & Events
    • Webinars
  • Contact Us
  • Download Center

ShangPharma Announces Strategic Corporate Restructuring of Shanghai ChemPartner

Mar 24, 2017 | Press Release |

Shanghai, China (March 24, 2017) – ShangPharma, a leading life science partnering organization providing high-quality and cost-effective drug development and discovery services, technology, and investment for the pharmaceutical and biotechnology industry, announced today the intent for a strategic corporate restructuring.

ShangPharma will be consolidating the Contract Research Organizations (CRO) and Contract Manufacturing Organizations (CMO) under Shanghai ChemPartner. These entities include ChemPartner Shanghai, ChemPartner Fengxian, ChemPartner Chengdu, ChemPartner US, ChemPartner Europe, China Gateway Pharmaceutical Development, China Gateway Biologics, ChemExplorer Hong Kong, and ChemExplorer Shanghai.

Currently, Shanghai ChemPartner’s intention is to enter the capital market in China, mainly through a merger approach.  By listing on either the Shanghai or Shenzhen stock exchange, ChemPartner seeks to leverage the capital market in China. Similar strategies have been adopted by several industry leaders.

“ShangPharma is committed to the best interests of our employees, our clients, our business partners, and our investors,” stated Michael Hui, Chairman and CEO of ShangPharma. “Executing a successful restructuring will provide access to capital and maximize shareholder value. Shanghai ChemPartner will continue to operate independently, and the current leadership team will remain intact. I am proud of the level of success the company has achieved, and I look forward to accomplishing this major milestone.”

“The corporate restructuring plan is an integral part of ShangPharma’s global growth strategy for its CRO and CMO organizations,” said Livia Legg, Chief Commercial Officer of Shanghai ChemPartner and General Manager of ChemPartner US and ChemPartner EU. “This strategic maneuver enables Shanghai ChemPartner to better serve its clients, expand its global presence and access new markets.”

Over the past fifteen years, ShangPharma has built a global workforce and comprehensive range of CRO and CMO services. Shanghai ChemPartner will continue to offer a broad range of drug discovery and development capabilities including discovery biologics, discovery chemistry, discovery biology, DMPK, CMC, and biologics manufacturing. ChemPartner serves a diverse global client base and operates laboratories and business offices in the US, Europe, China, and Japan.

Dr. Wei Tang, President of Shanghai ChemPartner stated, “The corporate restructuring will have no impact on ChemPartner’s routine business operations, and the company will continue to provide high quality services to its clients. ChemPartner is a strong organization comprised of hardworking, passionate people. We are committed to operational excellence and will remain a science driven, technology based organization.”

FOR MORE INFORMATION 

                                                                                                                                Livia Legg, MS, Chief Commercial Officer

news@chempartner.com

Tags: ChemPartnerShangPharmaStrategic Corporate Restructuring
3
Share

You also might be interested in

Berkeley Lights and ChemPartner Collaborate on Accelerating Antibody Discovery

Jun 28, 2018

EMERYVILLE, Calif., June 27, 2018 /PRNewswire/ — Berkeley Lights, Inc. (BLI), a leader[...]

ChemPartner at the 18th Shanghai International Froum on Biotechnology & Pharmaceutical Industry

ChemPartner at the 18th Shanghai International Froum on Biotechnology & Pharmaceutical Industry

Jun 22, 2016

The 18th International Forum on Biotechnology & Pharmaceutical Industry (Bio-Forum)[...]

Shanghai  ChemPartner  Announces Merger Deal Closure with Quantum

Shanghai ChemPartner Announces Merger Deal Closure with Quantum

Aug 16, 2018

SHANGHAI, Aug. 16, 2018 /PRNewswire/ -- Shanghai  ChemPartner, a leading life science organization[...]

Latest News

ChemPartner Makes Additional Investments in Biologics from Research to Manufacturing Capabilities

06/11/2020

Shanghai, China (June 9, 2020) – Shanghai ChemPartner...

ChemPartner Assists the Mount Sinai Health System in Producing Reagent for COVID-19 Research

05/12/2020

Shanghai, China (May 12, 2020) – Shanghai ChemPartner...

ChemPartner and the Gladstone Institutes Announce COVID-19 Research Collaboration

04/17/2020

SAN FRANCISCO, Calif. and SHANGHAI, China. (April 15, 2020)...

ChemPartner Introduces New State-of-the-Art Global Operation Center in Shanghai

04/02/2020

Shanghai, China (March 17, 2020) – Shanghai ChemPartner...

Dr. Jie Jack Li joins Shanghai ChemPartner as a Vice President of Discovery Chemistry

12/18/2019

Shanghai, China (December 17, 2019) – Shanghai ChemPartner...

Shanghai ChemPartner was awarded “TOP 10 CMOs in 2019”

Shanghai ChemPartner was awarded “TOP 10 CMOs in 2019”

07/19/2019

Contract manufacturers play a significant role when it comes...

Tag Cloud

2017 AACR Agreement Antibody Engineering art Berkeley Lights Best Life Science BIOtech Blend Boston Capital Market Chemistry ChemPartner Congratulates CPhI CPSA Shanghai 2016 CRO DMPK Exploratory Toxicology Labs layout Merger Deal PEGS PEGS CHINA Peptide Pharma Pharmacology product PTF Qidong Quantum Hi-Tech China Biological Research Facility San Diego San Francisco Shanghai Shanghai ChemPartner ShangPharma Sponsor Strategic Corporate Restructuring Tarveda Therapeutic Top 10 CMOs Vice President World ADC

Give us a Message

You can leave us a message by quick contact box and we'll get back to you, asap. Thanks!

Send Message

Logo

ChemPartner is a leading research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry.

Get started today.

Contact Us
  • Shanghai ChemPartner Co., Ltd.
  • 1F & 3F, Block A, 2829 JinKe Road, Zhangjiang Hi-Tech Park, PuDong New Area, Shanghai China, 201203
  • +86 21 5132 0088
  • contact@chempartner.com

© 2021 — Shanghai ChemPartner Co., Ltd. All Rights Reserved  About Us  Careers  Contact Us  Privacy Policy  Sitemap

  • Home
  • Contact
  • Buy Highend
Prev Next